WILMINGTON, Del.--(BUSINESS WIRE)--High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) continued to ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a ...

Enhertu isn’t a typical chemotherapy or immunotherapy drug but rather a combination of chemotherapy and targeted therapy, known as an antibody-drug conjugate. Enhertu works by using an antibody to ...

Second positive phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU in HER2 positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent ...

Daiichi Sankyo and AstraZeneca’s ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results ...

Based on DESTINY-Breast06 Phase III trial results which showed ENHERTU demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year Approval brings ...

Enhertu showed significant improvement in pathologic complete response rates in high-risk HER2-positive early-stage breast cancer compared with standard care. The DESTINY-Breast11 trial indicated ...

Enhertu significantly improved IDFS compared to Kadcyla, with a 53% risk reduction in invasive disease or death in high-risk, HER2-positive breast cancer patients. The DESTINY-Breast05 trial ...

How Do I Use Enhertu for Breast Cancer? Doses of Enhertu are given as an IV through a blood vessel in your arm over a period of time. Your dose will be given by a health care provider every 3 weeks at ...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy ...

Second positive Phase III trial of AstraZeneca (AZN) and Daiichi Sankyo’s ENHERTU in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in ...